Viridian Therapeutics, Inc.

DB:1S1 Stock Report

Market Cap: €1.5b

Viridian Therapeutics Valuation

Is 1S1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1S1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 1S1's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 1S1's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1S1?

Key metric: As 1S1 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 1S1. This is calculated by dividing 1S1's market cap by their current book value.
What is 1S1's PB Ratio?
PB Ratio3x
BookUS$518.61m
Market CapUS$1.57b

Price to Book Ratio vs Peers

How does 1S1's PB Ratio compare to its peers?

The above table shows the PB ratio for 1S1 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average12.8x
BIO3 Biotest
2.1x82.7%€1.4b
FYB Formycon
1.4x31.5%€821.0m
VSC 4SC
44.8xn/a€55.6m
HPHA Heidelberg Pharma
2.8x-33.0%€101.1m
1S1 Viridian Therapeutics
3x32.1%€1.6b

Price-To-Book vs Peers: 1S1 is good value based on its Price-To-Book Ratio (3x) compared to the peer average (12.8x).

Price to Book Ratio vs Industry

How does 1S1's PB Ratio compare vs other companies in the DE Biotechs Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
O7P NeuBase Therapeutics
0.1xn/aUS$1.39m
No more companies available in this PB range
1S1 3.0xIndustry Avg. 2.4xNo. of Companies3PB00.61.21.82.43+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 1S1 is expensive based on its Price-To-Book Ratio (3x) compared to the European Biotechs industry average (2.3x).

Price to Book Ratio vs Fair Ratio

What is 1S1's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1S1 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio3x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 1S1's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1S1 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€18.40
€38.36
+108.5%
21.2%€57.60€20.77n/a16
Nov ’25€19.10
€35.32
+84.9%
21.6%€50.39€19.80n/a16
Oct ’25€20.60
€35.32
+71.5%
21.6%€50.39€19.80n/a16
Sep ’25€13.30
€32.23
+142.3%
23.2%€42.13€18.32n/a16
Aug ’25€15.30
€32.41
+111.8%
23.4%€42.37€18.42n/a16
Jul ’25€11.90
€32.76
+175.3%
23.4%€42.82€18.62n/a16
Jun ’25€10.80
€33.85
+213.4%
21.7%€42.66€18.55n/a14
May ’25€12.50
€36.25
+190.0%
12.0%€42.37€27.63n/a14
Apr ’25€15.80
€36.25
+129.4%
12.0%€42.37€27.63n/a14
Mar ’25€17.10
€35.68
+108.7%
13.6%€42.45€26.76n/a15
Feb ’25€17.50
€36.08
+106.2%
14.9%€45.95€26.65n/a15
Jan ’25€19.90
€35.83
+80.1%
14.8%€45.55€26.42n/a15
Dec ’24€15.10
€36.59
+142.3%
16.1%€45.97€26.66n/a15
Nov ’24€11.70
€39.08
+234.0%
16.5%€53.86€28.35€19.1014
Oct ’24€14.10
€40.74
+189.0%
12.5%€53.35€32.76€20.6015
Sep ’24€16.50
€40.19
+143.6%
12.7%€52.07€31.97€13.3016
Aug ’24€16.80
€40.97
+143.9%
11.1%€50.76€32.06€15.3016
Jul ’24€21.60
€42.60
+97.2%
10.8%€52.65€36.94€11.9016
Jun ’24€22.00
€43.00
+95.5%
11.1%€53.13€37.28€10.8015
May ’24€24.80
€42.80
+72.6%
10.2%€52.15€36.60€12.5014
Apr ’24€22.60
€43.71
+93.4%
12.8%€57.20€36.90€15.8013
Mar ’24€30.40
€43.79
+44.1%
14.6%€57.87€32.67€17.1012
Feb ’24€32.80
€43.15
+31.5%
14.7%€56.82€32.07€17.5012
Jan ’24€26.60
€40.70
+53.0%
15.5%€53.74€31.11€19.9012
Dec ’23€23.80
€40.09
+68.4%
16.1%€54.15€31.35€15.1010
Nov ’23€19.70
€44.52
+126.0%
14.6%€58.71€38.11€11.709

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Regeneron Pharmaceuticals

US$80.0b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

RGO

US$705.00

7D

-7.1%

1Y

-3.8%

Amneal Pharmaceuticals

US$2.6b

Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.

2DT

US$7.60

7D

-6.2%

1Y

90.0%

Collegium Pharmaceutical

US$967.5m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$28.60

7D

0.7%

1Y

20.2%